Circulating biomarkers for prostate cancer

被引：0
作者：
Thomas Steuber
Pauliina Helo
Hans Lilja
机构：
[1] University Clinic Hamburg Eppendorf,Department of Urology
[2] Memorial Sloan-Kettering Cancer Center,Departments of Clinical Laboratories
来源：
World Journal of Urology | 2007年 / 25卷
关键词：
Prostate cancer; Biomarkers; PSA; Screening;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Due to its significant applicability for early detection, risk prediction and follow-up evaluation, prostate specific antigen (PSA) has revolutionized our ability to treat prostate cancer patients. With the prevalent use of PSA for early detection during the last two decades, disease characteristics have been altered towards early detected, localized tumors with a high chance of cure following local therapy. This advantage faces the risk of overdetection and overtreatment. In addition, PSA lacks both, sensitivity and specificity to accurately detect patients at risk of prostate cancer. Therefore, novel biomarkers are urgently needed to improve identification of men at risk of having the disease and to predict the natural behaviour of the tumor. Recent advances in the evaluation of high-throughput technologies have led to the discovery of novel candidate markers for prostate cancer. This article will briefly discuss current PSA-based strategies and review several novel biomarkers for prostate cancer, detectable in blood.
引用
收藏
页码：111 / 119
页数：8
相关论文
共 466 条
[1]  
Partin AW(1997)Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update Jama 277 1445-1451
[2]  
Kattan MW(1998)A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 766-771
[3]  
Subong EN(2002)Screening for prostate cancer with prostate-specific antigen: beware the biases Clin Chim Acta 315 71-97
[4]  
Walsh PC(2004)Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2239-2246
[5]  
Wojno KJ(2000)The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer Cancer 88 2398-2424
[6]  
Oesterling JE(2002)Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml J Urol 167 103-111
[7]  
Scardino PT(2007)Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44–50 years J Clin Oncol 25 431-436
[8]  
Pearson JD(1996)Age-specific reference ranges for serum PSA N Engl J Med 335 345-346
[9]  
Kattan MW(1997)Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies J Urol 158 2162-2167
[10]  
Eastham JA(1994)Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves J Urol 152 2031-2036
12345678910